Table 1.

Features of the PJP-population.

	PJP-Patients (n = 49)
Age (years)	53.5 ± 15.3
Male	36 (73.5%)
Mean interval KT-PJP (months), median [Q1; Q3]	13.4 [7.3; 54.4]
Baseline graft function (eGFR, MDRD, ml/min/1.73 m2), mean ± SD	40.4 ± 17.1
Immunosuppression features
Retransplantation	10 (20.4%)
Induction treatment
Anti-thymocyte globulin	30 (61.2%)
CD25 monoclonal antibody	19 (38.8%)
Immunosuppressive regimen
Steroid	36 (77.6%)
CNI	46 (93.9%)
MMF	41 (83.7%)
mTOR inhibitor	8 (16.3%)
Azathioprine	1 (2.0%)
Acute rejection (before PJP)	10 (20.4%)
Opportunistic infection (before PJP)	14 (28.6%)
Comorbidities
Pre-transplant diabetes	9 (18.4%)
New onset diabetes after transplantation	3 (6.1%)
Heart failure	5 (10.2%)
Chronic lung disease	4 (8.2%)
Parathyroidectomy (before transplantation)	2 (4.1%)
Symptoms at the hospital admission
Febrile dyspnea	25 (51.0%)
Isolated fever	2 (4.1%)
Non febrile respiratory symptoms	16 (32.7%)
Non febrile alteration of general condition	6 (12.2%)
Biological presentation at the hospital admission, mean ± SD
Corrected calcium serum levels (mg/dL)	10.0 ± 1.3
Serum Phosphorous levels (mg/dL)	3.7 ± 0.1
Serum PTH levels (pg/mL)	67.9 ± 20.2
CD4+ T lymphocytes (109/L)	377 ± 298
C-reactive protein (mg/dL)	5.9 ± 4.5
Microbiologic data
Pneumocystis identification, n (%)
Positive PCR	49 (100%)
Microscopic ascus identification and positive PCR	16 (32.7%)
PJP Treatment
Time to specific anti-infectious treatment initiation (days), median [Q1; Q3]	3 [1; 7]
Treatment duration, mean ± SD (days)	19.0 ± 6.9
TMP-SMX dose, mean ± SD (mg/kg/day)	42.6 ± 21.2
TMP-SMX discontinuation for adverse event, n(%)	10 (20.4)
Concomitant complications to PJP
Hypercalcemia, n (%)	18 (36.7%)
Acute kidney injury, n (%)	37 (75.6%)
Oxygen dependence, n (%)	12 (24.5%)
Transfer to Intensive Care Unit, n (%)	7 (14.3%)